

1 **FAR AWAY FROM HERD IMMUNITY TO SARS-CoV-2: results from a**
2 **survey in healthy blood donors in South Eastern Italy**

3
4 **Josè Ramòn Fiore¹, Michele Centra², Armando De Carlo^{3*}, Tommaso Granato², Annamaria**
5 **Rosa^{3*}, Michelina Sarno², Lucia De Feo², Mariantonietta Di Stefano¹, Maria L. D'Errico¹,**
6 **Sergio Lo Caputo¹, Rosella De Nittis⁴, Fabio Arena⁴, Gaetano Corso⁵, Maurizio**
7 **Margaglione⁶ Teresa Antonia Santantonio¹**

8
9 1) Department of Clinical and Experimental Medicine, Section of Infectious Diseases, University of
10 Foggia, School of Medicine, Foggia, Italy

11 2) Transfusion Medicine Center, Ospedali Riuniti University Hospital, Foggia, Italy

12 3) Laboratory analysis, Ospedali Riuniti University Hospital, Foggia, Italy

13 4) Department of Clinical and Experimental Medicine, Section of Microbiology, University of Foggia,
14 School of Medicine, Foggia, Italy

15 5) Department of Clinical and Experimental Medicine, Section of Clinical Biochemistry, University of
16 Foggia, School of Medicine, Foggia, Italy

17 6) Department of Clinical and Experimental Medicine, Section of Genetics, University of Foggia,
18 School of Medicine, Foggia, Italy

19
20 **Corresponding Author**

21 Jose Ramon Fiore MD, PhD

22 Department of Clinical and Experimental Medicine

23 Section of Infectious Diseases, University of Foggia

24 Ospedali Riuniti University Hospital

25 Via Luigi Pinto 1 71100 Foggia (Italy)

26 Email jose.fiore@unifg.it

27 **ABSTRACT**

28

29 Here we present results from a survey on anti-SARS-CoV-2 seroprevalence in healthy blood donors

30 from a low incidence COVID-19 area (Apulia region, South Eastern Italy).

31 Among 904 subjects tested, only in 9 cases (0.99%) antibodies against SARS-CoV-2 were

32 demonstrated. All the 9 seropositive patients were negative for the research of viral RNA by RT-

33 PCR in nasopharyngeal swab.

34 These data, along with those recently reported from other countries, clearly show that we are very

35 far from herd immunity and that the containment measures are at the moment the only realistic

36 instrument we have to slow the spread of the pandemic.

37

38

39 INTRODUCTION

40

41 Herd immunity is a concept in epidemiology that describes how people can collectively stave off
42 infections if some percentage of the population has immunity to it. When most of a population is
43 immune to an infectious disease, this provides indirect protection, or herd protection, to those who
44 are not immune (1)

45 There are two ways to achieve herd immunity: a large proportion of the population either gets
46 infected or gets a protective vaccine. Based on early estimates of SARS-CoV-2 infectiousness, it
47 should be likely needed at least 60-70% of the population to be immune to have herd protection (2).

48 However, more recently mathematical models suggest that lower thresholds could be enough to
49 place populations over the herd immunity threshold once as few as 43% (3) or even 10-20% of its
50 individuals are immune. (4)

51 It is therefore important and urgent to evaluate the extent of circulation (and thus of immunity to)
52 Of SARS-CoV-2 in the general populations of affected countries because this information should
53 guide the extent of reduction or increasing of preventive measures such as social distancing etc.

54 Italy registered the first imported cases of infection in January 31 2020 and after one week the first
55 local case. After that, a dramatic burden of infections was diagnosed: 235.278 cases (with 33.964
56 deaths) as for **June 8** 2020, with main clusters in Northern Italy. As a whole, 390
57 infections/100.000 inhabitants. In Foggia (Apulia region, South Eastern Italy) the first case was
58 observed in March the 1st and as for **June 8**, 1162 cases were diagnosed with an incidence of 187
59 cases/100.000 inhabitants (5)).

60 Although the total number of diagnosed infections is moderate, we miss clear information regarding
61 the number of individuals in the general population that became immune, possibly acquiring the
62 virus with no or mild symptoms.

63 Studies on blood donor cohorts are useful to evaluate the prevalence, incidence and natural course
64 of infectious diseases in the general population and may thus help to assess both the viral
65 circulation and the evolution of the COVID-19 outbreak.

66 We therefore studied a group of healthy blood donors from Foggia province for the presence of IgM
67 and IgG to antibodies to SARS-CoV-2 to examine the circulation of the virus in the general
68 population three months after the local start of the epidemic.

69

70 **SUBJECTS, MATERIAL AND METHODS**

71

72 **SUBJECTS**

73 The main study cohort was composed of blood donors, who were apparently healthy subjects, aged
74 18-65 years. Exclusion criteria were active infection or medical conditions, recent surgical
75 procedures, stay in endemic areas, reported risk factors for parenterally acquired infections, chronic
76 degenerative conditions, diagnosis of cancer or high risk of cardiovascular events. All donors
77 underwent clinical examination, medical history evaluation and biochemical testing. All subjects
78 should had been free of recent symptoms possibly related to COVID-19, nor had close contact with
79 confirmed cases, symptoms free during the preceding 14 days, nor had contacts with suspected
80 cases.

81 Each blood donor signed written informed consents allowing for testing for communicable diseases,
82 storing anonymized data and biological materials for diagnostic/research purposes, and use of their
83 anonymous data for clinical research.

84 A total of 904 blood donors, referring to the Transfusional Center at the “Ospedali Riuniti”
85 University Hospital (Foggia, Italy) were included in the study and subjected to the search for anti-
86 SARS-CoV-2 antibodies, in the period May1-31 2020. In the case of positivity, subjects were re-
87 called and RT-PCR for detection SARS-CoV-2 from nasopharyngeal swabs was performed.

88

89 **METHODS**

90

91 **Detection of anti SARS Cov 2 antibodies**

92 Anti-SARS-CoV-2 IgG and IgM were analyzed by using a chemiluminescent analytical assay
93 (CLIA) commercially available kit (New Industries Biomedical Engineering Co., Ltd [Snibe],
94 Shenzhen, China) performed according to the manufacturers instructions. Reagent wells were
95 coated with recombinant structural protein CoV-S (spike) and e CoV-N (nucleocapside) of SARS-
96 CoV-2 for both IgM and IgG assay. For IgM assay, the microspheres were coated with a
97 monoclonal antibody to capture human IgM followed by the addition of recombinant antigen from
98 virus 2019-nCoV marked with amino-butyl-ethyl-isoluminol (ABEI). The samples, serum or
99 plasma, were diluted by instrument. The relative light units (RLU) detected is proportional to the
100 concentration of IgG/M in sample. An RLU-ratio of the measurement of each sample to the
101 supplied calibrator was calculated. According to manufacturer instructions for the IgG assay
102 arbitrary units of <1 was considered negative, 1.0 to 1.1 borderline and >1.1 positive; for IgM, an
103 AU/mL <0.9 was considered negative, 0.9 to 1.0 borderline and > 1.0 positive.

104 Manufacturers claimed that the calculated clinical sensitivities of IgM and IgG were 78.65% and
105 91.21%, respectively, while specificities of IgM and IgG were 97.50% and 97.3%, respectively.

106

107 **RT-PCR for detection SARS-CoV-2 from nasopharyngeal swabs**

108 Viral RNA was extracted within 2 hours from sample collection using the STARMag 96 X 4
109 Universal Cartridge kit with the Microlab NIMBUS IVD instrument according to the
110 manufacturer's instructions (Seegene Inc. Seoul, Korea). Amplification and detection of target
111 genes (N, E and RdRP) was performed using the commercially available kit Allplex™ 2019-nCoV
112 Assay (Seegene Inc. Seoul, Korea) with the CFX96™ instrument (Bio-Rad, Hercules, CA).
113 Results interpretation was performed with the Seegene Viewer software.

114

115 **RESULTS**

116

117 A total of 904 subjects were enrolled in this study (666 males and 239 females) ranging from 18 to
118 65 years (Table 1). Among them, 9 tested positive for antibodies to SARS-CoV-2: in 8 cases only
119 IgG antibodies were found while in 1 case both IgG and IgM were detected, with a percentage of
120 positivity in the blood donor population of 0.99 %.

121 No statistical differences were observed in the rate of antibody detection according to the sex and
122 the age.

123 None of these subjects had clinical signs or symptoms and laboratory parameters alterations; all of
124 them tested negative for RT-PCR research of SARS-CoV-2 RNA in two nasopharyngeal swabs
125 performed on two consecutive days.

126

127

128

129 **DISCUSSION**

130

131 Herd immunity is the resistance to the spread of a contagious disease that results if a sufficient
132 proportion of a population is immune due to natural infection or mass vaccination.

133 Because an effective COVID-19 vaccine is not yet available, herd immunity can be established if a
134 large proportion of immune persons exist in a population to confer indirect protection from
135 infection to susceptible individuals. The breadth of the barrier required to achieve herd immunity
136 depends in large part on viral spread and infectivity. In the nomenclature of epidemiology, the basic
137 reproduction number or R_0 and the classical formula for calculating a herd immunity threshold is
138 $1 - 1/R_0$. The higher the R_0 , the higher the threshold required for achieving herd immunity. Other
139 important factors in calculating herd immunity thresholds include the number of social interactions
140 and their durations, innate differences in individual immune responses, and divergent exposures to
141 the infectious microbe (1)

142 People who recover from a COVID-19 coronavirus infection, at least for some time, develop
143 immunity to the virus (6).

144 The disease-induced herd immunity threshold for SARS-CoV-2, according to various
145 epidemiologists, is believed to be around 60 to 70 percent (2) More recently, some researchers have
146 reported lower thresholds: from 43% to just 10 to 20% of the population (3, 4), suggesting that we
147 could reach herd immunity thresholds by natural infections in the setting of COVID-19 pandemic.

148 Recently, data from Spain, France and Italy (7-9) countries that adopted strict lockdown measures
149 indicate a very low seroprevalence in the general population (4.4%, 5% and 7.1%, respectively).
150 Noteworthy, even in Sweden, a country that decided for a herd immunity strategy, with very light
151 restrictions on daily life, antibodies to SARS-CoV-2 were detectable in only 7.5% of the general
152 population in Stockholm (10).

153 In other geographical regions, serosurveys in healthy individuals demonstrated a very low rate of
154 positivity for SARS-CoV-2 (11-15).

155 In our study, we confirm a low rate of antibodies against SARS-CoV-2 on a group of blood donors
156 from a geographical region with a moderate incidence (187 cases/100.000 inhabitants vs the
157 national data of 390 infections/100.000 inhabitants).

158 A limitation of our study is that the enrolled population (18-65 years old) is representative of only a
159 part of the general population, since in Italy 22% of the individuals is aged >65 years (16)

160 However, presented data are relevant in that they refer to the more acting/interacting group of the
161 population, also important from a productive point of view.

162 Certainly, we are far away from herd immunity and even from the more optimistic projections of
163 threshold (10 to 20% of the population) to adopt more relaxed strategies.

164 In conclusion, strengthening herd immunity to control the COVID-19 epidemic is not a viable
165 option as large numbers of people are expected to become infected and many may die from
166 COVID-19. Preventive measures, including physical distancing, remain essential to contain the
167 spread of infection until herd immunity can be safely acquired with the vaccine. Health authorities
168 should take in account these considerations when facing the public health measures to be adopted
169 throughout the COVID-19 transition phases.

170
171

172

173

174

175

176

- 177 1) Metcalf C.J.E, Ferrari M., Graham A.L., Grenfell B.T. Understanding Herd
178 Immunity. Trends Immunol. 2015;36(12):753-755.
179
- 180 2) Randolph H.E., Barreiro L.B. Herd Immunity: Understanding COVID-19. Immunity.
181 2020;52(5):737-741.
182
- 183 3) Britton T., Trapman P., Ball F.G. The disease-induced herd immunity level for Covid-19 is
184 substantially lower than the classical herd immunity level.
185 medRxiv 2020.05.06.20093336; doi: <https://doi.org/10.1101/2020.05.06.20093336>
186
- 187 4) Gabriela M., Gomes M., Corder R. M., King, J. G., Langwig K. E., Souto-Maior, C. et al,
188 Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity
189 threshold. medRxiv 2020.04.27.20081893. <https://doi.org/10.1101/2020.04.27.20081893>
190
- 191 5) [http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?li
192 ngua=italiano&menu=notizie&p=dalministero&id=4870](http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=4870)
193
- 194 6) Braun J., Loyal L., Frensch M., Wendisch D., Georg P., Kurth F. et al. Presence of SARS-
195 CoV-2 reactive T cells in COVID-19 patients and healthy donors.
196 MedRxiv 2020.04.17.20061440; doi: <https://doi.org/10.1101/2020.04.17.20061440>
197
- 198 7) Ministerio de Sanidad, Consumo y Bienestar Social Estudio Ene COVID 19: Primera ronda
199 estudio nacional de sero-epidemiologia de la infeccion por SARS-COV-2 en Espana.
200 Informe preliminar 13 de Mayo de 2020
201 <https://www.mscbs.gob.es/gabinetePrensa/notaPrensa/pdf/ENE-C140520115618104.pdf>
202

- 203 8) Salje H., Tran Kiem C., Lefrancq N., Courtejoie N., Bosetti P., Paireau J. et al. Estimating
204 the burden of SARS-CoV-2 in France [published online ahead of print, 2020 May
205 13]. Science. 2020;eabc3517. doi:10.1126/science.abc3517
206
- 207 9) Valenti L., Bergna A., Pelusi S., Facciotti F., Lai A., Tarkowski M. et al. SARS-CoV-2
208 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak.
209 medRxiv 2020.05.11.20098442 doi: <http://org/10.1101/2020.05.11.20098442>
210
- 211 10) [https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/maj/forsta-
212 resultat-en-fran-pagaende-undersokning-av-antikroppar-for-covid-19-
213 virus/?fbclid=IwAR0BK_fKQ2l9q4upW4LbMH4celkIaTXIyrvwvOW1RbaoxkJ1DKdEGP
214 Txx6w](https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/maj/forsta-
212 resultat-en-fran-pagaende-undersokning-av-antikroppar-for-covid-19-
213 virus/?fbclid=IwAR0BK_fKQ2l9q4upW4LbMH4celkIaTXIyrvwvOW1RbaoxkJ1DKdEGP
214 Txx6w)
215
- 216 11) Sughayer M.A., Mansour A., Al Nuirat A., Souan L., Ghanem M., Siag M. Covid-19
217 Seroprevalence rate in healthy blood donors from a community under strict lockdown
218 measures
219 medRxiv 2020.06.06.20123919; doi: <https://doi.org/10.1101/2020.06.06.20123919>
220
- 221 12) Kai Wang-to K., Chi-Chung Cheng V., Cai J. P., Chan K. H., Chen L. L., Wong L. H. et
222 al. Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei
223 province, China: a multicohort study. Lancet microbes, June 2020 DOI: 10.1016/S2666-
224 5247(20)30053-7
225
- 226 13) Filho L.A., Landmann Szwarcwald C., de Oliveira Garcia Mateos S., Monteiro Ponce de
227 Leon A., de Andrade Medronho R., Gonçalves Veloso V et al., Seroprevalence of IgG and

228 IgM anti-SARS-CoV-2 among voluntary blood donors in Rio de Janeiro, Brazil Scielo
229 Electronic Library Online preprint, doi: <https://doi.org/10.1590/SciELOPreprints.404>

230

231 14) Sood N., Simon P., Ebner P., Eichner D., Reynolds J., Bendavid E. et al. Seroprevalence of
232 SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on
233 April 10-11, 2020 [published online ahead of print, 2020 May 18]. JAMA. 2020;e208279.
234 doi:10.1001/jama.2020.8279

235

236 15) Ng D., Goldgof G., Shy B., Andrew L., Balcerak J., Bapat S. P. et al. SARS-CoV-2
237 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco
238 Bay Area. Preprint. medRxiv. 2020;2020.05.19.20107482. Published 2020 May 25.
239 doi:10.1101/2020.05.19.20107482

240 16) [https://www.tuttitalia.it/statistiche/indici-demografici-struttura-](https://www.tuttitalia.it/statistiche/indici-demografici-struttura-popolazione/#:~:text=Struttura%20della%20popolazione%20dal%202002,anziani%2065%20anni%20ed%20oltre.)
241 [popolazione/#:~:text=Struttura%20della%20popolazione%20dal%202002,anziani%2065%2](https://www.tuttitalia.it/statistiche/indici-demografici-struttura-popolazione/#:~:text=Struttura%20della%20popolazione%20dal%202002,anziani%2065%20anni%20ed%20oltre.)
242 [0anni%20ed%20oltre.](https://www.tuttitalia.it/statistiche/indici-demografici-struttura-popolazione/#:~:text=Struttura%20della%20popolazione%20dal%202002,anziani%2065%20anni%20ed%20oltre.)

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263 **TABLE 1:**

264

265 Detection of antibodies to SARS Cov 2 in 904 healthy blood donors according to sex and age

	n°	Positive n°	%
Total	904	9	0.99
Males	665	5	0.75
Females	239	4	1.6
Ages (range)	n°	n°	%
Group I (18 – 25)	112	1	0.89
Group II (26 – 35)	195	4	2.0
Group III (36 – 45)	202	1	0.49
Group IV (46 – 55)	246	0	0
Group IV (56– 65)	149	3	2.0

266

267

268

269

270